Sponsors look to collaborate on comparator drugs
New research suggests comparator drugs and co-therapies used in clinical studies comprise a larger proportion of clinical research budgets than previously thought—and contribute significantly to the rising cost of drug development.
Early adopters implement risk-based monitoring pilot programs
The drug development industry has begun to move forward in supporting risk-based monitoring models, yet sponsors and CROs remain uncertain about the best ways to implement this new approach and how regulatory agencies will respond. As a result, companies have launched experiments that, in the short term, will mean uncertainty and change across the clinical research enterprise.
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.